Better clinical outcomes if HAART started before CD4 cell count falls below 200

This article is more than 21 years old. Click here for more recent articles on this topic

Individuals who start HAART when their CD4 cell count is below 200 cells/mm3 are more likely to progress to AIDS or death than patients who initiate anti-HIV therapy with a CD4 cell count between 201 – 350 cells, even if they achieve durable HIV suppression, according to US research published in the December 1st edition of the Journal of Infectious Diseases.

The study provides one of the strongest bodies of evidence to date that delaying HAART until a CD4 cell count falls below 200 cells/mm3 has a clear clinical disadvantage, and the investigators emphasise that this disadvantage should be strongly stressed in treatment guidelines.

The investigators conducted an observational study which followed 1173 patients who started HAART between July 1996 and summer 2002. Individuals were stratified according to their baseline CD4 cell counts (below 200 cells/mm3; 201 – 350 cells/mm3; and above 350 cells/mm3). Data were gathered on the number of patients achieving durable HIV suppression (a viral load below 400 copies/mL) and the development of new AIDS-defining infections and deaths.

Glossary

p-value

The result of a statistical test which tells us whether the results of a study are likely to be due to chance and would not be confirmed if the study was repeated. All p-values are between 0 and 1; the most reliable studies have p-values very close to 0. A p-value of 0.001 means that there is a 1 in 1000 probability that the results are due to chance and do not reflect a real difference. A p-value of 0.05 means there is a 1 in 20 probability that the results are due to chance. When a p-value is 0.05 or below, the result is considered to be ‘statistically significant’. Confidence intervals give similar information to p-values but are easier to interpret. 

observational study

A study design in which patients receive routine clinical care and researchers record the outcome. Observational studies can provide useful information but are considered less reliable than experimental studies such as randomised controlled trials. Some examples of observational studies are cohort studies and case-control studies.

lymphocyte

A type of white blood cell that is important in the immune system. Includes B cells (B lymphocytes, which produce circulating antibodies) and T cells (T lymphocytes, which are responsible for cell-mediated immunity).

trend

In everyday language, a general movement upwards or downwards (e.g. every year there are more HIV infections). When discussing statistics, a trend often describes an apparent difference between results that is not statistically significant. 

disease progression

The worsening of a disease.

Among all the study patients, HAART was taken for a median of 29 months, and median duration of total follow-up was 36 months.

Individuals who started HAART with a CD4 cell count below 200 cells/mm3 were significantly less likely to achieve durable HIV suppression. Even if patient with a lower CD4 cell count achieved a sustained viral load below 400 copies/mL there was a trend for them to experience more clinical events (AIDS or death) than individuals whose baseline CD4 cell count was between 201 cells/mm3 - 350 cells/mm3 (p=0.09), and were significantly more likely to progress than patients whose baseline CD4 cell count was above 350 cells/mm3 (p=0.01).

However, the investigators found no benefit was gained from starting HAART with a CD4 cell count above 350 cells/mm3 as there was no difference in disease progression between patients who stated HAART at this level and patients whose baseline CD4 cell count was between 201 cells/mm3 and 350 cells/mm3 (p=0.40).

Commenting on their findings, the investigators note that their study had a longer duration of follow-up (a quarter of individuals contributed 54 months or more of data) than the observational studies upon which current treatment guidelines are based.

They conclude that their findings “strongly support initiating therapy at CD4 lymphocyte counts >200 cells/mm3 and suggests that treatment guidelines should clearly state the importance of initiating therapy before CD4 lymphocyte counts decrease to 3.

Further information on this website

US HIV guidelines: choose either lopinavir or efavirenz in first-line treatment - news story

BHIVA treatment guidelines 2003

Further information

Early vs late initiation of antiretroviral therapy for HIV infection: a scientific roundtable meeting - a Medscape report on a US expert meeting examining recent data on this subject.

References

Sterling TR et al. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort. Journal of Infectious Diseases 188: 1659 – 65, 2003.